ADC Therapeutics
ADCT’s CEO Ameet Mallik participated and presented in two investor conferences in September: HC Wainwright Annual Global Investment Conference and Cantor Global Healthcare Conference.
Elevation Oncology
Elevation announced that FDA has granted Fast Track designation to EO-3021, a differentiated ADC, for the treatment of patients with advanced or metastatic gastric and gastroesophageal junction cancer expressing CLDN18.2 that has progressed on or after prior therapy.
Mersana Therapeutics
Short interest of Mersana increased by 21 % to 10,306,527 reported on September 15, compared to 8,487,549 on August 15.
Sutro Biopharma
Sutro announced updated data from the ongoing Phase 1b study of luveltamab tazevibulin (luvelta) in combination with bevacizumab for patients with epithelial ovarian cancer (EOC) in a poster presentation at the 2024 ESMO Congress. The 4.3 mg/kg of luvelta in combination with standard dose of bevacizumab (15 mg/kg) every 3 weeks resulted in a 56% ORR in patients with late-stage ovarian cancer and was selected to be the recommended phase 2 dose.
ImmunityBio
ImmunityBio announced positive results from its QUILT 3.055 trial demonstrating long-term extended survival of 14 months to as much as five years for patients with advanced NSCLC being treated with checkpoint inhibitors. An oral presentation of the data was presented at the World Congress on Lung Cancer in San Diego. The phase 2b study of Anktiva in combination with Keytruda or Opdivo in multiple tumor types including NSCLC who failed CPI showed long-term overall survival of 57 % and 34 % at 12 and 18 months respectively.
Mural Oncology
Mural hosted a virtual Investor Day and provided new clinical insight into the trial design, statistical assumptions, and progress of the company’s late-stage trials of nemvaleukin. Key data readouts for the company’s late-stage, potentially registrational trials of nemvaleukin are expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma.
